Drug intelligence / Profile preview

DWJ1386

Development stage: Unknown
Lead developer: Daewoong Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

DWJ1386 is a small molecule drug developed by Daewoong Pharmaceutical. It is being investigated as a fixed-dose combination product intended for the treatment of gastrointestinal ulcers. The drug has been evaluated in at least one phase 1 clinical trial comparing its pharmacokinetics and safety to the co-administration of two other compounds, DWC20155 and DWC20156, in healthy subjects. The precise mechanism of action and molecular targets for DWJ1386 have not been publicly disclosed[1][2][5].

Other names: fexuprazan and artemisia asiatica extract combination

Targets

ATP4A (Potassium–transporting ATPase alpha chain 1)

Beyond the preview

Go deeper on DWJ1386.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DWJ1386.

Explore the full profile